Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIB Breast Cancer: early-phase trial registry
1 of 24 indexed Stage IIIB Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 1 currently recruiting · #686 of 28,707 conditions by registered trial count
Stage IIIB Breast Cancer: 24 US clinical trials tracked, 1 recruiting.
Stage IIIB Breast Cancer is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 4 of these trials.
Enrollment posture brief
Registry condition stage-iiib-breast-cancer
OPEN 1 | RECR 4% | LATE 2 | EARLY 15 | RANK #686 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Stage IIIC Breast Cancer (4% recruiting · 24 trials)
Stage IIIB Breast Cancer lists 1 open slots (4% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIB Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIB Breast Cancer is recruiting below its size-band peers.
1 of 24 indexed trials (4.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IIIB Breast Cancer research.
University of Washington accounts for 4 of 24 trials (16.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IIIB Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 57 among the 24 trials that report a genuine target (sentinel values excluded). 19 of those (79.2%) plan for fewer than 100 participants.
-
Stage IIIB Breast Cancer research is mostly interventional.
22 interventional and 2 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Laura Huppert, MD, BA
NCT03971409
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
NCT01953588
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ECOG-ACRIN Cancer Research Group
NCT01824836
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ECOG-ACRIN Cancer Research Group
NCT02445391
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
NCT01525966
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
City of Hope Medical Center
NCT01730833
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
NCT02315196
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
University of Washington
NCT02157051
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
City of Hope Medical Center
NCT02827877
Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer
Stanford University
NCT03050463
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Gary Morrow
NCT02002533
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
NCT00513695
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
NCT00470301
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT01869764
Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer
National Cancer Institute (NCI)
NCT00516243
MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment
Wake Forest University Health Sciences
NCT02702830
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT02046421
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
University of Washington
NCT01928186
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT01281150
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
George W. Sledge Jr.
NCT03364348
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
University of Washington
NCT00425672
Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors
Fred Hutchinson Cancer Center
NCT02662335
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01818063
Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT03102866
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIB Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIB Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIB Breast Cancer page
24 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage IIIB Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most Stage IIIB Breast Cancer trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIB Breast Cancer condition card totals 24 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.